GSK steps in for J&J’s li­cense of Ar­row­head’s he­pati­tis B drug, plans com­bo study with its own can­di­date

British drug­mak­er GSK plans to ac­quire an ex­per­i­men­tal he­pati­tis B drug from John­son & John­son and its de­vel­op­er Ar­row­head Phar­ma­ceu­ti­cals and then com­bine the siR­NA with its own late-stage ther­a­py to de­vel­op an even more ef­fec­tive po­ten­tial treat­ment.

Per the deal, an­nounced Tues­day morn­ing, GSK will pay less than $100 mil­lion up­front to J&J and Ar­row­head for glob­al rights to de­vel­op and mar­ket JNJ-3989, a source fa­mil­iar with the mat­ter told End­points News.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER